Cargando…

Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects

Filgotinib, a preferential Janus Kinase‐1 inhibitor, is approved in Europe and Japan for treatment of rheumatoid arthritis and is being developed for treatment of other chronic inflammatory diseases. Three drug‐drug interactions studies were conducted in healthy subjects to evaluate the effect of P‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsueh, Chia‐Hsiang, Anderson, Kacey, Shen, Gong, Yun, Chohee, Qin, Ann, Othman, Ahmed A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841438/ https://www.ncbi.nlm.nih.gov/pubmed/34498807 http://dx.doi.org/10.1111/cts.13152

Ejemplares similares

Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants
por: Anderson, Kacey, et al.
Publicado: (2021)

Filgotinib: A Clinical Pharmacology Review
por: Namour, Florence, et al.
Publicado: (2022)

Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects
por: Topletz‐Erickson, Ariel R., et al.
Publicado: (2020)

Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies
por: Meng, Amy, et al.
Publicado: (2022)

Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2020)

Correction to: Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2021)

Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial
por: Danese, Silvio, et al.
Publicado: (2023)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
por: Balsa, Alejandro, et al.
Publicado: (2023)

Inhibitory Effects of Green Tea and (–)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein
por: Knop, Jana, et al.
Publicado: (2015)

Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
por: Combe, Bernard, et al.
Publicado: (2022)

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
por: Hibi, Toshifumi, et al.
Publicado: (2023)

In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs
por: George, Blessy, et al.
Publicado: (2021)

Anterior and Posterior Ocular Biometry in Healthy Chinese Subjects: Data Based on AS-OCT and SS-OCT
por: Huang, Wenbin, et al.
Publicado: (2015)

Correction to: Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Expression of MATE1, P-gp, OCTN1 and OCTN2, in epithelial and immune cells in the lung of COPD and healthy individuals
por: Berg, Tove, et al.
Publicado: (2018)

Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
por: Ceckova, Martina, et al.
Publicado: (2018)

Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial
por: Dotan, Iris, et al.
Publicado: (2023)

Divergent Regulation of OCT and MATE Drug Transporters by Cadmium Exposure
por: Yang, Hong, et al.
Publicado: (2021)

PPARα-Dependent Modulation by Metformin of the Expression of OCT-2 and MATE-1 in the Kidney of Mice
por: Arruda, Adriano Cleis, et al.
Publicado: (2020)

Analysis of OCT1, OCT2 and OCT3 gene polymorphisms among Type 2 diabetes mellitus subjects in Indian ethnicity, Malaysia
por: Ghasan Abood Al-Ashoor, Sabah, et al.
Publicado: (2022)

A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions
por: Türk, Denise, et al.
Publicado: (2020)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy
por: Dal Buono, Arianna, et al.
Publicado: (2022)

Transport Turnover Rates for Human OCT2 and MATE1 Expressed in Chinese Hamster Ovary Cells
por: Zhang, Xiaohong, et al.
Publicado: (2022)

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

PPAR-α Deletion Attenuates Cisplatin Nephrotoxicity by Modulating Renal Organic Transporters MATE-1 and OCT-2
por: Freitas-Lima, Leandro Ceotto, et al.
Publicado: (2020)

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
por: Werth, Victoria P, et al.
Publicado: (2021)

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study
por: Price, Elizabeth, et al.
Publicado: (2022)

A drug–drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers
por: Shibata, Mai, et al.
Publicado: (2020)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

Rapid Regulation of Human Multidrug and Extrusion Transporters hMATE1 and hMATE2K
por: Kantauskaitė, Marta, et al.
Publicado: (2020)

Light conditions influence optic nerve OCT angiography parameter in healthy subjects with neutral pupils
por: Nelis, Pieter, et al.
Publicado: (2023)

Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study
por: Loftus, Edward V, et al.
Publicado: (2022)

Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor
por: Namour, Florence, et al.
Publicado: (2018)

Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives
por: Tanaka, Yoshiya, et al.
Publicado: (2023)

Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn’s disease and is responsive to filgotinib
por: Reinisch, Walter, et al.
Publicado: (2022)

Optimizing visualization in enhanced depth imaging OCT in healthy subjects and patients with retinal pigment epithelial detachment
por: Reznicek, Lukas, et al.
Publicado: (2012)

U-Shaped Effect of Blood Pressure on Structural OCT Metrics and Retinal Perfusion in Ophthalmologically Healthy Subjects
por: Pappelis, Konstantinos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4f89r4mp9gdr2kmgql262tbavd